$BMRN Recent News Biotech comeback stalls as W
Post# of 103143
Posted On: 06/21/2014 7:21:01 AM
$BMRN Recent News
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
Major U.S. benchmarks pull in to first support 12:27 p.m. March 10, 2014 - Michael Ashbaugh
BioMarin shares rally as FDA mutes criticism of rare disorder drug 6:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 12:10 p.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 6:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 11:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 1:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 3:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 5:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 12:56 p.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 1:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 12:39 p.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 1:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 12:17 p.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 12:49 p.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 7:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 10:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 10:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate 2:19 p.m. June 20, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – SHPG CBST BMRN SLXP 7:45 a.m. June 20, 2014 - InvestorPlace.com
The Trader Daily 7:30 a.m. June 19, 2014 - RealMoney.com
Amicus Therapeutics Still A "Show Me" Story 2:11 p.m. June 12, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com
How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? 7:53 a.m. June 12, 2014 - TheStreet.com
The Trader Daily 7:30 a.m. June 12, 2014 - RealMoney.com
7 Biotechnology Stocks to Buy Now 5:45 a.m. June 11, 2014 - InvestorPlace.com
UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical 8:41 a.m. June 9, 2014 - benzinga.com
How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? 7:54 a.m. June 9, 2014 - TheStreet.com
Benzinga's Top Upgrades 6:52 a.m. June 9, 2014 - benzinga.com
The Trader Daily 7:30 a.m. June 5, 2014 - RealMoney.com
Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders 10:30 a.m. June 4, 2014 - TheStreet.com
Drugs Stocks On The Rise With Help From 3 Stocks 1:02 p.m. June 3, 2014 - TheStreet.com
BioMarin's Pipeline Advances - Analyst Blog 11:40 a.m. May 29, 2014 - Zacks.com
The Trader Daily 7:30 a.m. May 29, 2014 - RealMoney.com
A Tale of Diversification 2:00 p.m. May 19, 2014 - RealMoney.com
Top Biotech Stocks for Cancer Cures from Cowen 8:08 a.m. May 16, 2014 - 247WallSt.com
Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders 10:30 a.m. May 14, 2014 - TheStreet.com
'Mad Money' Lightning Round: BioMarin Is for Real 6:00 a.m. May 8, 2014 - TheStreet.com
Relypsa Adds Industry Veterans Daniel K. Spiegelman and kenneth J. Hillan to Its Board of Directors 4:06 p.m. June 19, 2014 - GlobeNewswire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease 8:02 a.m. May 27, 2014 - GlobeNewswire
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex 8:29 a.m. May 7, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma 9:15 a.m. May 6, 2014 - PR Newswire - PRF
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th 8:02 a.m. May 6, 2014 - GlobeNewswire
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress 4:06 p.m. May 1, 2014 - GlobeNewswire
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages 11:08 a.m. April 28, 2014 - GlobeNewswire
Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics 8:00 a.m. April 25, 2014 - PR Newswire - PRF
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET 8:02 a.m. April 16, 2014 - GlobeNewswire
Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma 11:15 a.m. April 15, 2014 - PR Newswire - PRF
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver 9:31 a.m. April 14, 2014 - PR Newswire - PRF
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets 8:02 a.m. April 14, 2014 - GlobeNewswire
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin 8:00 a.m. April 11, 2014 - PR Newswire - PRF
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma 11:55 a.m. March 26, 2014 - PR Newswire - PRF
BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors 8:01 a.m. March 21, 2014 - GlobeNewswire
Critical Alerts For Voxeljet, QUALCOMM, Canadian Solar, NQ Mobile, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. March 19, 2014 - PR Newswire - PRF
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update 8:16 a.m. March 19, 2014 - GlobeNewswire
BioMarin Announces Pricing of Public Offering of Common Stock 9:00 a.m. March 5, 2014 - GlobeNewswire
Biotech comeback stalls as Wall Street starts to worry 12:45 p.m. March 25, 2014 - Russ Britt
Major U.S. benchmarks pull in to first support 12:27 p.m. March 10, 2014 - Michael Ashbaugh
BioMarin shares rally as FDA mutes criticism of rare disorder drug 6:25 p.m. Nov. 15, 2013 - Russ Britt
German DAX ends at record as Europe stocks rally 12:10 p.m. Sept. 19, 2013 - Sara Sjolin
BioMarin rallies 7.6% on Roche takeover report 6:30 a.m. Sept. 19, 2013 - Sara Sjolin
S&P 500 retests the 50-day moving average 11:07 a.m. Sept. 9, 2013 - Michael Ashbaugh
Biotech ETF's breakout: bullish for stocks overall? 1:11 p.m. Sept. 5, 2013 - blogs.marketwatch.com
Acura, BioMarin mount independent rallies on their own positive news 3:28 p.m. July 1, 2013 - Russ Britt
After the close: Biogen slips, Epizyme slows, BioMarin stalls 5:57 p.m. June 4, 2013 - Russ Britt
Lofty expectations hit BioMarin in development of new cancer drugs 12:56 p.m. June 3, 2013 - Russ Britt
Get out of junk stocks now 1:14 p.m. March 22, 2013 - Mark Hulbert
Charting a slow-motion test of the 2012 peak 12:39 p.m. Jan. 11, 2013 - Michael Ashbaugh
U.S. benchmarks sustain the 2013 breakout 1:00 p.m. Jan. 4, 2013 - Michael Ashbaugh
Meet the S&P 500’s new range 12:17 p.m. Dec. 13, 2012 - Michael Ashbaugh
Charting a lackluster recovery attempt 12:49 p.m. Nov. 21, 2012 - Michael Ashbaugh
‘Aggressive’ comment hits Express Scripts 7:03 p.m. Nov. 5, 2012 - Russ Britt
BioMarin's GALNS meets primary endpoint in trial 10:24 a.m. Nov. 5, 2012 - MarketWatch.com
Biomarin says trial results meet primary endpoint 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Biomarin says its GALNS Phase III trial posiitve 8:23 a.m. Nov. 5, 2012 - Greg Morcroft
Staking out major support 10:46 a.m. Oct. 3, 2012 - Michael Ashbaugh
Biomarin Pharmaceutical (BMRN) Marked As A Barbarian At The Gate 2:19 p.m. June 20, 2014 - TheStreet.com
Hottest Healthcare Stocks Now – SHPG CBST BMRN SLXP 7:45 a.m. June 20, 2014 - InvestorPlace.com
The Trader Daily 7:30 a.m. June 19, 2014 - RealMoney.com
Amicus Therapeutics Still A "Show Me" Story 2:11 p.m. June 12, 2014 - Seeking Alpha
Top Analyst Upgrades and Downgrades: Apache, Apple, HP, Qualcomm, Sprouts and More 7:58 a.m. June 12, 2014 - 247WallSt.com
How Will BioMarin (BMRN) Stock Respond To This Analyst Upgrade Today? 7:53 a.m. June 12, 2014 - TheStreet.com
The Trader Daily 7:30 a.m. June 12, 2014 - RealMoney.com
7 Biotechnology Stocks to Buy Now 5:45 a.m. June 11, 2014 - InvestorPlace.com
UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical 8:41 a.m. June 9, 2014 - benzinga.com
How WIll This Upgrade Affect Biomarin Pharmaceutical (BMRN) Stock Today? 7:54 a.m. June 9, 2014 - TheStreet.com
Benzinga's Top Upgrades 6:52 a.m. June 9, 2014 - benzinga.com
The Trader Daily 7:30 a.m. June 5, 2014 - RealMoney.com
Insider Trading Alert - TWO, CCL And BMRN Traded By Insiders 10:30 a.m. June 4, 2014 - TheStreet.com
Drugs Stocks On The Rise With Help From 3 Stocks 1:02 p.m. June 3, 2014 - TheStreet.com
BioMarin's Pipeline Advances - Analyst Blog 11:40 a.m. May 29, 2014 - Zacks.com
The Trader Daily 7:30 a.m. May 29, 2014 - RealMoney.com
A Tale of Diversification 2:00 p.m. May 19, 2014 - RealMoney.com
Top Biotech Stocks for Cancer Cures from Cowen 8:08 a.m. May 16, 2014 - 247WallSt.com
Insider Trading Alert - WMGI, MSM And BMRN Traded By Insiders 10:30 a.m. May 14, 2014 - TheStreet.com
'Mad Money' Lightning Round: BioMarin Is for Real 6:00 a.m. May 8, 2014 - TheStreet.com
Relypsa Adds Industry Veterans Daniel K. Spiegelman and kenneth J. Hillan to Its Board of Directors 4:06 p.m. June 19, 2014 - GlobeNewswire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease 8:02 a.m. May 27, 2014 - GlobeNewswire
Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex 8:29 a.m. May 7, 2014 - PR Newswire - PRF
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma 9:15 a.m. May 6, 2014 - PR Newswire - PRF
BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th 8:02 a.m. May 6, 2014 - GlobeNewswire
BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress 4:06 p.m. May 1, 2014 - GlobeNewswire
The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages 11:08 a.m. April 28, 2014 - GlobeNewswire
Earnings Schedules, Acquisition Agreements, and Financial Results Release - Analyst Notes on Mallinckrodt, BioMarin, Salix Pharmaceuticals, St. Jude Medical and Quest Diagnostics 8:00 a.m. April 25, 2014 - PR Newswire - PRF
BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET 8:02 a.m. April 16, 2014 - GlobeNewswire
Analysts View on Biotech Equities -- Research on Organovo Holdings, BioMarin Pharma, Vertex Pharma, and Spectrum Pharma 11:15 a.m. April 15, 2014 - PR Newswire - PRF
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver 9:31 a.m. April 14, 2014 - PR Newswire - PRF
FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets 8:02 a.m. April 14, 2014 - GlobeNewswire
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin 8:00 a.m. April 11, 2014 - PR Newswire - PRF
Biotech Stocks Technical Review -- Research on BioCryst Pharma, Spectrum Pharma, BioMarin Pharma, and Vertex Pharma 11:55 a.m. March 26, 2014 - PR Newswire - PRF
BioMarin Appoints Pioneer in Personalized Medicine, Dennis J. Slamon, M.D., Ph.D., to Board of Directors 8:01 a.m. March 21, 2014 - GlobeNewswire
Critical Alerts For Voxeljet, QUALCOMM, Canadian Solar, NQ Mobile, and BioMarin Pharmaceuticals Released By InvestorsObserver 9:31 a.m. March 19, 2014 - PR Newswire - PRF
Catalyst Pharmaceutical Partners Announces Fourth Quarter and Year-End 2013 Financial Results and Provides Corporate Update 8:16 a.m. March 19, 2014 - GlobeNewswire
BioMarin Announces Pricing of Public Offering of Common Stock 9:00 a.m. March 5, 2014 - GlobeNewswire
(0)
(0)